title: New drugs and preparations for open-angle glaucoma in adults.
abstract: Primary (or chronic) open-angle glaucoma (POAG or COAG) may be asymptomatic but causes progressive optic nerve damage with significant loss of visual field. Treatments aim to lower intraocular pressure (IOP) by reducing the production of aqueous humour and/or increasing its drainage. Here we update our previous articles to reflect new drugs, preservative-free preparations and fixed-dose drug combinations for POAG.
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000069580:Bimatoprost / Q000627:therapeutic use; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D011460:Prostaglandins F / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; C485333:tafluprost; D000077338:Latanoprost; D000069580:Bimatoprost